Phathom Pharmaceuticals
PHAT

$18.43

1.55%

Market Cap: $1.26B

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 15 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

755% more call options, than puts

Call options by funds: $5.18M | Put options by funds: $606K

140% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 20

13% more funds holding in top 10

Funds holding in top 10: 8 [Q1] → 9 (+1) [Q2]

6.86% more ownership

Funds ownership: 89.75% [Q1] → 96.61% (+6.86%) [Q2]

5% more capital invested

Capital invested by funds: $557M [Q1] → $583M (+$25.3M) [Q2]

0% more funds holding

Funds holding: 113 [Q1] → 113 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 18

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

35%

downside

Avg. target

$25

37%

upside

High target

$28

52%

upside

15 analyst ratings

14 positive

93%

1 neutral

7%

0 negative

0%

Needham Joseph Stringer 69% 1-year accuracy 90 / 130 met price target	41%upside $26	Buy Reiterated	13 Sept 2024
Needham Joseph Stringer 69% 1-year accuracy 90 / 130 met price target	41%upside $26	Buy Reiterated	6 Sept 2024
Needham Joseph Stringer 69% 1-year accuracy 90 / 130 met price target	41%upside $26	Buy Reiterated	30 Aug 2024
Needham Joseph Stringer 69% 1-year accuracy 90 / 130 met price target	41%upside $26	Buy Reiterated	23 Aug 2024
Needham Joseph Stringer 69% 1-year accuracy 90 / 130 met price target	41%upside $26	Buy Reiterated	19 Aug 2024

See Analyst Rankings

Financial journalist opinion

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its common stock and pre-funded warrants to purchase 2,608,922 shares of common stock. The shares of common stock are being sold at a price of $11.50 per share and the pre-funded warrants are being sold at a price of $11.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130 million. The offering is expected to close on or about August 20, 2024, subject to satisfaction of customary closing conditions.

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Paul Choi - Goldman Sachs Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to Phathom Pharmaceuticals Second Quarter 2024 Earnings Results Call.

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $0.84 per share a year ago.

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter of 2024, and provided recent business updates.

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA represents the first major innovation in GERD treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S. A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J.

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation.

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze

One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company's proportion of shorted stock is publicly available, it's pretty easy to see which companies are expected to lose value.

Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in June:

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham & Company Paul Choi - Goldman Sachs Annabel Samimy - Stifel Matthew Caufield - H.C. Wainright Operator Hello, and welcome to Phathom Pharmaceuticals First Quarter 2024 Earnings Results Call.

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

See News Rankings